Siamab is developing therapeutic antibodies targeting glycan alterations present in the majority of solid tumors — including colon, lung, ovarian, breast, prostate, and pancreatic cancer. Cancer cells mutate the glycans present on the cell surface to enable tissue invasion and metastases. Targeting glycans with antibodies offers the potential to provide patients with significant benefits in reducing tumor burden by both killing tumor cells and blocking metastatic behavior.
Acquisition for a Positive Exit
August 19, 2019 – Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma Transaction Validates Anti-TACA Therapeutic Approach for Treatment of Solid Tumors.
